Not a good buy right now for an impatient buyer: the primary trend is still bearish (bearish MAs, MACD histogram negative and expanding), and price has slipped below the first support (~12.02).
Oversold RSI (RSI_6 ~13) increases the odds of a short-term bounce, but without an Intellectia buy signal, the odds favor a continued choppy/down tape rather than a clean reversal.
Options positioning is very call-heavy (bullish skew), yet that alone is not enough to override deteriorating technicals + limited near-term catalysts.
Momentum: MACD histogram -0.204 and negatively expanding → bearish momentum is strengthening rather than stabilizing.
Condition: RSI_6 at ~13.09 → deeply oversold; statistically supports a reflex bounce, but oversold can stay oversold in downtrends.
Levels: Pivot 12.98 (now overhead resistance). S1 12.018 has been lost (current 11.86), so next downside reference is S2 11.423. Upside resistance zones: 13.94 (R1), 14.54 (R2).
Pattern-based forward look (provided): ~70% chance next day -0.15%, next week +3.36%, next month +2.23% → modest rebound odds, but not a strong edge versus the current downtrend.
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Positioning/Sentiment: Extremely low put/call OI ratio (0.03) and put/call volume ratio (0.08) → strongly bullish/speculative call-skew sentiment.
Volatility: IV 30d ~55.82 vs HV ~56.02 (roughly in-line) → options aren’t pricing an outsized move relative to realized volatility.
IV context: IV percentile ~43 and IV rank ~34.8 → mid-range, not “panic-high,” not “cheap-low.”
Caveat on signal quality: Call-heavy skew can reflect speculation rather than informed conviction; without price confirmation (trend reversal), it’s weaker as a standalone buy trigger.
Technical Summary
Sell
8
Buy
5
Positive Catalysts
Technical mean-reversion setup: RSI deeply oversold, increasing probability of a near-term bounce.
Loss narrowing trend: Net income and EPS improved YoY (though still negative), which can support sentiment if revenue stabilizes.
Quant/pattern hint (provided): modestly positive next-week and next-month bias (+3.36% / +2.23%).
Neutral/Negative Catalysts
increases risk of a move toward S2 (~11.42).
Financial Performance
Latest quarter: 2025/Q3.
Revenue: 92.472M, down -27.83% YoY → negative growth trend.
Profitability: Net income improved to -82.156M (loss narrowed, +70.96% YoY improvement), and EPS improved to -0.55 (+57.14% YoY improvement), but the company remains loss-making.
Margin: Gross margin 60.78%, slightly down (-0.69% YoY) → stable-to-slightly softer margin profile while revenue contracts.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent trend: rating moved more cautious.
Key change: JPMorgan (2025-11-24) downgraded EHang to Neutral from Overweight and cut PT to $13 from $21, citing a slower and more conditional regulatory/commercialization pathway over the next 12–24 months.
Wall Street cons view (cons): timing risk—commercialization/regulatory ramp appears slower, reducing near-term upside and compressing conviction.
Wall Street analysts forecast EH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EH is 21 USD with a low forecast of 13 USD and a high forecast of 26 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast EH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EH is 21 USD with a low forecast of 13 USD and a high forecast of 26 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 11.270
Low
13
Averages
21
High
26
Current: 11.270
Low
13
Averages
21
High
26
UBS
AJ Rice
Neutral -> Buy
upgrade
$12
AI Analysis
2026-01-08
Reason
UBS
AJ Rice
Price Target
$12
AI Analysis
2026-01-08
upgrade
Neutral -> Buy
Reason
UBS analyst AJ Rice upgraded Enhabit to Buy from Neutral with a price target of $12, up from $8.50. The firm believes the the final home health rule provides more clarity around Enhabit's future earnings outlook. The firm cites this and the stock's "discounted valuation" for the upgrade.
JPMorgan
Beatrice Lam
Overweight -> Neutral
downgrade
$21 -> $13
2025-11-24
Reason
JPMorgan
Beatrice Lam
Price Target
$21 -> $13
2025-11-24
downgrade
Overweight -> Neutral
Reason
JPMorgan analyst Beatrice Lam downgraded EHang to Neutral from Overweight with a price target of $13, down from $21. Electric vertical take-off and landing aircraft remain a potential global megatrend and a core pillar of China's low-altitude economy plan, but the regulatory pathway is proving slower and more conditional than expected, the analyst tells investors in a research note. The firm downgrades the stock as its recent Guangzhou immersion tour and management/expert discussions point to a more gradual commercialization phase over the next 12-24 months.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for EH
